Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
President 42 -
Corporate Secretary - -
Treasurer 60 -
Director TitleAgeSince
Director/Board Member 42 -
Date Insider Type Main position Quantity % Market Cap.
27/07/20Tender

Chief Executive Officer

21,978 0.3026%
27/07/20Tender

Chief Financial Officer

6,239 0.0859%
27/07/20Tender

Chairman

2,135 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.93% - - 16.07M
-2.41%+0.14%+39.53%+154.43% 1,035B
+1.07%+3.48%+53.75%+50.64% 574B
+1.32%+0.22%+18.35%+65.35% 397B
+0.77%+0.77%+21.19%+15.95% 324B
-0.85%-0.68%+23.44%+14.94% 281B
+0.44%+5.39%+25.86%+35.39% 278B
+1.66%+1.20%-44.41%-47.37% 193B
+0.32%+1.61%+19.48%+63.42% 191B
-0.22%-2.76%+12.08%+61.30% 156B
Average -0.13%+0.82%+18.81%+46.00% 381.1B
Weighted average by Cap. -0.74%+1.04%+28.20%+71.91%
Logo Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!